C
CMPX
vs
S&P 500
S&P 500
Over the past 12 months, CMPX has underperformed S&P 500, delivering a return of -32% compared to S&P 500's +19% growth.
Stocks Performance
CMPX vs S&P 500
Performance Gap
CMPX vs S&P 500
Performance By Year
CMPX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Compass Therapeutics Inc.
Glance View
Compass Therapeutics is a biotechnology company that develops antibody-based drugs, mainly for cancer. Its work centers on finding immune and tumor targets, designing antibodies that can bind to those targets, and testing these candidates in clinical trials. The company does not sell consumer products; its business is built around discovering and advancing medicines that could become prescription therapies. The company’s main customers are not patients directly, but larger drug companies, hospitals, and eventually doctors and health systems if a drug wins approval. Today it makes money mainly through research partnerships, licensing deals, and the long path to possible future drug sales if its own programs succeed. That means most of its value comes from its pipeline of experimental medicines rather than from a broad commercial product line. What makes Compass different is its focus on antibody science and on hard-to-treat cancers. In this industry, a company like Compass acts as a drug developer that takes early research forward to the point where a larger partner may help fund development, or where the company itself can pursue approval and commercialization. Its role is to turn lab discoveries into medicines that can be tested in real patients.
